Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy.
Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.
Busse
William
W
University of Wisconsin, Madison Medical School, Department of Medicine, 15/220 Clinical Science Center, 600 Highland Ave, Madison, WI 53792-2454, USA. wwb@medicine.wisc.edu
Kraft
Monica
M
D000328:Adult; D002648:Child; D003545:Cysteine / Q000037:antagonists & inhibitors* / Q000276:immunology*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000276:immunology*; D015289:Leukotrienes / Q000276:immunology*; D010641:Phenotype; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*
D018836:Inflammation Mediators; D015289:Leukotrienes; C112381:cysteinyl-leukotriene; D003545:Cysteine